Cisplatin and Metabolic Reprogramming: Next-Generation Strategies for Overcoming Chemoresistance

Introduction

Cisplatin (CDDP), also known as cis-diamminedichloroplatinum(II), stands as a cornerstone DNA crosslinking agent for cancer research and a gold standard in platinum-based chemotherapy. Its potent anticancer efficacy—spanning ovarian, non-small cell lung, head and neck squamous cell carcinoma, nasopharyngeal, and gastric cancers—derives from its ability to disrupt DNA replication and transcription, inducing cell cycle arrest and apoptosis. Yet, despite its foundational role in oncology, the persistent challenge of chemotherapy resistance, especially in aggressive malignancies like cholangiocarcinoma, demands innovative approaches that move beyond canonical DNA damage paradigms to embrace the complex interplay of metabolic and immune factors in the tumor microenvironment.

Cisplatin’s Mechanism of Action: DNA Crosslinking and Apoptosis Induction

DNA Damage and Crosslink Formation

As a DNA crosslinking agent, Cisplatin enters cancer cells and forms both intra- and inter-strand crosslinks at guanine bases. These adducts disrupt the progression of DNA polymerases, leading to inhibition of DNA replication and transcription—critical processes for rapidly dividing tumor cells. This primary mechanism is a focal point in numerous studies and has been well-documented as the basis for cisplatin’s cytotoxicity (see in-depth mechanistic review). However, this article advances the discussion by integrating emerging metabolic insights with classical DNA repair pathways.

Activation of Apoptotic Pathways

Cisplatin-induced DNA lesions trigger a cascade of cellular responses culminating in apoptosis. Notably, the tumor suppressor p53 is activated, which in turn upregulates pro-apoptotic pathways and can initiate cell cycle arrest. Downstream, caspase-dependent apoptosis is executed via caspase-3 and caspase-9 activation, marking a central role for caspase signaling pathways in mediating cell death. Additionally, cisplatin increases the production of reactive oxygen species (ROS), fueling oxidative stress and lipid peroxidation, which further amplifies apoptotic signaling. These combined effects have made cisplatin a valuable tool for apoptosis assay development and studies of cell cycle regulation.

Metabolic Reprogramming and Cisplatin Resistance: A New Frontier

While DNA damage and apoptosis induction are foundational, a growing body of research underscores the importance of metabolic reprogramming in shaping the response to cisplatin and the emergence of chemotherapy resistance. The tumor microenvironment (TME) is metabolically dynamic, and metabolic shifts can profoundly influence drug sensitivity, immune evasion, and overall treatment outcomes.

PDHA1 Succinylation and Chemotherapy Sensitivity

Recent groundbreaking work (Nature Communications, 2025) has elucidated a critical link between post-translational modification of metabolic enzymes and chemotherapy resistance. In cholangiocarcinoma, a highly aggressive liver cancer, succinylation of the pyruvate dehydrogenase alpha 1 (PDHA1) at lysine 83 enhances enzyme activity, driving increased conversion of pyruvate to acetyl-CoA and fueling the tricarboxylic acid (TCA) cycle. This metabolic flux leads to the accumulation of alpha-ketoglutaric acid (α-KG) in the TME.

Crucially, α-KG acts as a signaling metabolite, activating the OXGR1 receptor on macrophages and triggering MAPK (ERK-dependent) signaling, which suppresses antigen presentation (notably via MHC-II downregulation) and promotes immune escape. This immune suppression facilitates tumor progression and contributes to the development of chemotherapy resistance, limiting cisplatin's efficacy. The study further demonstrated that pharmacological inhibition of PDHA1 succinylation (using CPI-613) sensitizes tumors to gemcitabine and cisplatin, highlighting a new therapeutic axis for overcoming resistance.

Implications for Cancer Cell Apoptosis and ROS Signaling

Metabolic reprogramming also impacts oxidative stress responses. Elevated α-KG and altered TCA cycle activity can modulate the balance between ROS generation and scavenging, influencing the threshold for apoptosis in response to DNA crosslinking agents. This interplay suggests that targeting metabolic vulnerabilities could augment cisplatin-induced apoptosis, especially in tumors with robust antioxidant defenses.

Advanced Applications: Integrating Metabolic and Apoptotic Pathways in Cancer Research

Beyond Conventional Models: New Avenues for Cisplatin-Based Studies

Traditional research has often focused on cisplatin’s effects in in vitro cytotoxicity assays and in vivo tumor xenograft inhibition studies. However, the integration of metabolic and immunological parameters—such as monitoring succinylation status, α-KG levels, and macrophage polarization—represents a paradigm shift. These advanced applications enable researchers to:

• Decipher the molecular underpinnings of chemotherapy resistance in diverse tumor models.
• Investigate the crosstalk between DNA damage responses and metabolic adaptation.
• Design apoptosis assays that account for both caspase-dependent and metabolic stress-induced cell death.
• Elucidate how ERK-dependent apoptotic signaling and ROS generation vary across metabolic states.

This multi-dimensional approach is particularly valuable for translational cancer research, where overcoming chemoresistance remains a primary clinical challenge.

Optimizing Experimental Protocols: Solubility, Storage, and Handling

Cisplatin’s physicochemical properties are critical for reliable experimental results. It is insoluble in water and ethanol but dissolves readily in dimethylformamide (DMF) at concentrations ≥12.5 mg/mL. Researchers should avoid using DMSO as a solvent, as it can inactivate cisplatin’s activity. For maximum stability, store cisplatin as a powder at 4°C, protected from light; solutions should be freshly prepared before use. These best practices align with APExBIO’s recommendations and ensure the reproducibility of apoptosis assays and tumor xenograft inhibition studies.

Comparative Analysis: A Multifaceted View of Cisplatin Research

Much of the extant literature, including the article "Scenario-Driven Solutions: Cisplatin (SKU A8321) for Reliable Cancer Research", provides pragmatic guidance on protocol optimization and troubleshooting for apoptosis and chemoresistance studies. While these resources are invaluable for day-to-day experimental design, the present article extends the discussion by synthesizing recent discoveries in metabolic regulation and their implications for cisplatin sensitivity. By interweaving metabolic, immunological, and classical DNA damage perspectives, we offer a holistic framework that enables researchers to innovate beyond conventional protocols and address the root causes of chemotherapy resistance.

Similarly, in contrast to "Cisplatin in Cancer Research: Ferroptosis, Chemoresistance, and Apoptosis Assays", which emphasizes ferroptosis and resistance mechanisms, this article uniquely focuses on the interface between metabolic signaling, immune evasion, and apoptotic responses—especially as elucidated by recent omics and post-translational modification research in cholangiocarcinoma.

Translational Perspectives: Overcoming Chemotherapy Resistance

The clinical translation of these findings is profound. As demonstrated in the referenced Nature Communications study, targeting PDHA1 succinylation not only alters cancer cell metabolism but also reprograms the tumor immune microenvironment, restoring macrophage antigen presentation and enhancing cisplatin efficacy. This approach provides a blueprint for combinatorial therapies: using metabolic inhibitors alongside cisplatin or similar platinum-based agents to break multidimensional resistance barriers.

Moreover, this research opens avenues for biomarker discovery—such as monitoring PDHA1 succinylation or α-KG levels—to predict and track chemotherapy response. These strategies could be especially transformative in hard-to-treat cancers where traditional DNA damage and apoptosis markers are insufficient.

Best Practices for Cisplatin Use in Advanced Cancer Research

• Model Selection: Incorporate in vitro and in vivo systems that allow for metabolic and immunological interrogation, such as tumor xenograft models with immune cell profiling.
• Apoptosis Assays: Combine caspase-dependent readouts with ROS and metabolic stress markers to capture the full spectrum of cisplatin-induced cell death.
• Chemotherapy Resistance Studies: Leverage genetic and pharmacological modulation of metabolic enzymes (e.g., PDHA1) to dissect resistance mechanisms and identify synergistic drug combinations.
• Data Interpretation: Integrate omics analyses (proteomics, metabolomics) to contextualize apoptotic and chemoresistance phenotypes within broader metabolic networks.

Conclusion and Future Outlook

The evolution of cisplatin research—from a focus on DNA crosslinking and caspase-dependent apoptosis to the integration of metabolic, oxidative stress, and immune signaling—heralds a new era in oncology. By embracing the complexity of chemotherapy resistance and leveraging advances in metabolic reprogramming, researchers can develop more effective, tailored strategies for cancer therapy. APExBIO’s cisplatin (A8321) remains a pivotal reagent for these next-generation studies, enabling precise interrogation of DNA damage, apoptosis, and metabolic adaptation in cancer models.

Future investigations should prioritize the dissection of metabolic-immune crosstalk, the validation of novel biomarkers of resistance, and the rational design of combinatorial regimens that exploit tumor vulnerabilities. The synergy between DNA crosslinking agents, metabolic modulators, and immunotherapies promises to redefine the landscape of cancer treatment and improve patient outcomes.